Cerebrospinal fluid β-amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE ε4 allele

Trey Sunderland, Nadeem Mirza, Karen T. Putnam, Gary Linker, Deepa Bhupali, Rob Durham, Holly Soares, Lida Kimmel, David Friedman, Judy Bergeson, Gyorgy Csako, James A. Levy, John J. Bartko, Robert M. Cohen

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Cerebrospinal fluid (CSF) measures of β-amyloid 1-42 and tau are linked with the known neuropathology of Alzheimer's disease (AD). Numerous lines of evidence have also suggested that individuals with at least one APOE ε4 allele on chromosome 19 are at increased risk of developing AD. We tested these CSF markers in groups of subjects with AD and healthy older control subjects, using the absence or presence of the APOE ε4 allele as a predictive variable in the search for possible prognostic biomarkers of AD. We assessed the levels of β-amyloid 1-42 and total tau in the CSF of 292 subjects (142 control subjects and 150 subjects with mild-to-moderate AD), who were research participants at the National Institute of Mental Health. The group of control subjects was enriched with a high percentage of subjects with a positive family history of AD. All subjects underwent extensive global cognitive testing. When divided according to the absence or presence of the APOE ε4 allele, the control subjects with at least one ε4 allele had significantly lower CSF β-amyloid 1-42 but not tau levels than control subjects without an APOE ε4 allele (p < 01). As expected, the AD patients had lower levels of CSF β-amyloid 1-42 and higher CSF tau levels than the normal control group (p <. 01). The association of APOE ε4 allele and lower, more AD-like levels of CSF β-amyloid 1-42 in older control subjects is consistent with previous studies showing possible neuroimaging and cognitive abnormalities with ε4 carriers and suggests that CSF β-amyloid 1-42 decreases might represent an early biomarker of AD. Longitudinal follow-up is of course required to verify whether this biomarker is indeed predictive of clinical conversion to AD.

Original languageEnglish (US)
Pages (from-to)670-676
Number of pages7
JournalBiological Psychiatry
Volume56
Issue number9
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

Amyloid
Cerebrospinal Fluid
Alzheimer Disease
Alleles
Biomarkers
tau-1 monoclonal antibody
National Institute of Mental Health (U.S.)
Chromosomes, Human, Pair 19
Control Groups
Neuroimaging
Research

Keywords

  • β-amyloid
  • Alzheimer's disease
  • APOE
  • Cerebrospinal fluid
  • tau

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Cerebrospinal fluid β-amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease : The effect of APOE ε4 allele. / Sunderland, Trey; Mirza, Nadeem; Putnam, Karen T.; Linker, Gary; Bhupali, Deepa; Durham, Rob; Soares, Holly; Kimmel, Lida; Friedman, David; Bergeson, Judy; Csako, Gyorgy; Levy, James A.; Bartko, John J.; Cohen, Robert M.

In: Biological Psychiatry, Vol. 56, No. 9, 01.11.2004, p. 670-676.

Research output: Contribution to journalArticle

Sunderland, T, Mirza, N, Putnam, KT, Linker, G, Bhupali, D, Durham, R, Soares, H, Kimmel, L, Friedman, D, Bergeson, J, Csako, G, Levy, JA, Bartko, JJ & Cohen, RM 2004, 'Cerebrospinal fluid β-amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE ε4 allele', Biological Psychiatry, vol. 56, no. 9, pp. 670-676. https://doi.org/10.1016/j.biopsych.2004.07.021
Sunderland, Trey ; Mirza, Nadeem ; Putnam, Karen T. ; Linker, Gary ; Bhupali, Deepa ; Durham, Rob ; Soares, Holly ; Kimmel, Lida ; Friedman, David ; Bergeson, Judy ; Csako, Gyorgy ; Levy, James A. ; Bartko, John J. ; Cohen, Robert M. / Cerebrospinal fluid β-amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease : The effect of APOE ε4 allele. In: Biological Psychiatry. 2004 ; Vol. 56, No. 9. pp. 670-676.
@article{82f3a89b73284ee5828ed15073205428,
title = "Cerebrospinal fluid β-amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE ε4 allele",
abstract = "Cerebrospinal fluid (CSF) measures of β-amyloid 1-42 and tau are linked with the known neuropathology of Alzheimer's disease (AD). Numerous lines of evidence have also suggested that individuals with at least one APOE ε4 allele on chromosome 19 are at increased risk of developing AD. We tested these CSF markers in groups of subjects with AD and healthy older control subjects, using the absence or presence of the APOE ε4 allele as a predictive variable in the search for possible prognostic biomarkers of AD. We assessed the levels of β-amyloid 1-42 and total tau in the CSF of 292 subjects (142 control subjects and 150 subjects with mild-to-moderate AD), who were research participants at the National Institute of Mental Health. The group of control subjects was enriched with a high percentage of subjects with a positive family history of AD. All subjects underwent extensive global cognitive testing. When divided according to the absence or presence of the APOE ε4 allele, the control subjects with at least one ε4 allele had significantly lower CSF β-amyloid 1-42 but not tau levels than control subjects without an APOE ε4 allele (p < 01). As expected, the AD patients had lower levels of CSF β-amyloid 1-42 and higher CSF tau levels than the normal control group (p <. 01). The association of APOE ε4 allele and lower, more AD-like levels of CSF β-amyloid 1-42 in older control subjects is consistent with previous studies showing possible neuroimaging and cognitive abnormalities with ε4 carriers and suggests that CSF β-amyloid 1-42 decreases might represent an early biomarker of AD. Longitudinal follow-up is of course required to verify whether this biomarker is indeed predictive of clinical conversion to AD.",
keywords = "β-amyloid, Alzheimer's disease, APOE, Cerebrospinal fluid, tau",
author = "Trey Sunderland and Nadeem Mirza and Putnam, {Karen T.} and Gary Linker and Deepa Bhupali and Rob Durham and Holly Soares and Lida Kimmel and David Friedman and Judy Bergeson and Gyorgy Csako and Levy, {James A.} and Bartko, {John J.} and Cohen, {Robert M.}",
year = "2004",
month = "11",
day = "1",
doi = "10.1016/j.biopsych.2004.07.021",
language = "English (US)",
volume = "56",
pages = "670--676",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Cerebrospinal fluid β-amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease

T2 - The effect of APOE ε4 allele

AU - Sunderland, Trey

AU - Mirza, Nadeem

AU - Putnam, Karen T.

AU - Linker, Gary

AU - Bhupali, Deepa

AU - Durham, Rob

AU - Soares, Holly

AU - Kimmel, Lida

AU - Friedman, David

AU - Bergeson, Judy

AU - Csako, Gyorgy

AU - Levy, James A.

AU - Bartko, John J.

AU - Cohen, Robert M.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Cerebrospinal fluid (CSF) measures of β-amyloid 1-42 and tau are linked with the known neuropathology of Alzheimer's disease (AD). Numerous lines of evidence have also suggested that individuals with at least one APOE ε4 allele on chromosome 19 are at increased risk of developing AD. We tested these CSF markers in groups of subjects with AD and healthy older control subjects, using the absence or presence of the APOE ε4 allele as a predictive variable in the search for possible prognostic biomarkers of AD. We assessed the levels of β-amyloid 1-42 and total tau in the CSF of 292 subjects (142 control subjects and 150 subjects with mild-to-moderate AD), who were research participants at the National Institute of Mental Health. The group of control subjects was enriched with a high percentage of subjects with a positive family history of AD. All subjects underwent extensive global cognitive testing. When divided according to the absence or presence of the APOE ε4 allele, the control subjects with at least one ε4 allele had significantly lower CSF β-amyloid 1-42 but not tau levels than control subjects without an APOE ε4 allele (p < 01). As expected, the AD patients had lower levels of CSF β-amyloid 1-42 and higher CSF tau levels than the normal control group (p <. 01). The association of APOE ε4 allele and lower, more AD-like levels of CSF β-amyloid 1-42 in older control subjects is consistent with previous studies showing possible neuroimaging and cognitive abnormalities with ε4 carriers and suggests that CSF β-amyloid 1-42 decreases might represent an early biomarker of AD. Longitudinal follow-up is of course required to verify whether this biomarker is indeed predictive of clinical conversion to AD.

AB - Cerebrospinal fluid (CSF) measures of β-amyloid 1-42 and tau are linked with the known neuropathology of Alzheimer's disease (AD). Numerous lines of evidence have also suggested that individuals with at least one APOE ε4 allele on chromosome 19 are at increased risk of developing AD. We tested these CSF markers in groups of subjects with AD and healthy older control subjects, using the absence or presence of the APOE ε4 allele as a predictive variable in the search for possible prognostic biomarkers of AD. We assessed the levels of β-amyloid 1-42 and total tau in the CSF of 292 subjects (142 control subjects and 150 subjects with mild-to-moderate AD), who were research participants at the National Institute of Mental Health. The group of control subjects was enriched with a high percentage of subjects with a positive family history of AD. All subjects underwent extensive global cognitive testing. When divided according to the absence or presence of the APOE ε4 allele, the control subjects with at least one ε4 allele had significantly lower CSF β-amyloid 1-42 but not tau levels than control subjects without an APOE ε4 allele (p < 01). As expected, the AD patients had lower levels of CSF β-amyloid 1-42 and higher CSF tau levels than the normal control group (p <. 01). The association of APOE ε4 allele and lower, more AD-like levels of CSF β-amyloid 1-42 in older control subjects is consistent with previous studies showing possible neuroimaging and cognitive abnormalities with ε4 carriers and suggests that CSF β-amyloid 1-42 decreases might represent an early biomarker of AD. Longitudinal follow-up is of course required to verify whether this biomarker is indeed predictive of clinical conversion to AD.

KW - β-amyloid

KW - Alzheimer's disease

KW - APOE

KW - Cerebrospinal fluid

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=7444271086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444271086&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2004.07.021

DO - 10.1016/j.biopsych.2004.07.021

M3 - Article

C2 - 15522251

AN - SCOPUS:7444271086

VL - 56

SP - 670

EP - 676

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 9

ER -